The management of chronic rhinosinusitis in clinical practice: An International Survey

D. Passali, G.C. Passali, M. Piemonte, C. Cingi, G. Ciprandi, International Study Group

Article ID: 5539
Vol 35, Issue 1S2, 2021
DOI: https://doi.org/10.23812/21-1supp2-9
Received: 11 March 2021; Accepted: 11 March 2021; Available online: 11 March 2021; Issue release: 11 March 2021

Abstract

Chronic rhinosinusitis (CRS) is a common disease and is currently classified in two main phenotypes: CRS with nasal polyps (CRSwNP) and CRS without nasal polyps (CRSsNP). A panel of international experts conducted the present survey. A questionnaire, containing 25 questions, was completed by each member of the panel. About half of patients with suspected CRS had confirmed diagnosis. CRSwNP affected 31% of CRS patients. Endoscopy and CT were ever performed. Rhinitis and asthma were frequent comorbidities. Intranasal corticosteroids were prescribed on average in 86% of patients. Nonadrenergic compounds were prescribed by 71% of experts. Surgery for CRSwNP was performed in about half of patients; repeated intervention occurred in about one/third. In conclusion, the current survey demonstrated that CRS requires thorough diagnostic work-up, and the most common therapeutic approach is mainly based on intranasal corticosteroids, non-adrenergic decongestants, and surgery.


Keywords

Survey;chronic rhinosinusitis;nasal polyps;intranasal corticosteroids;non-adrenergic decongestants;surgery


References

Supporting Agencies



Copyright (c) 2021 D. Passali, G.C. Passali, M. Piemonte, C. Cingi, G. Ciprandi, International Study Group on Chronic Rhinosinusitis




This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).